NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Apr 24, 2024 04:40PM
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023 Aug 21, 2023 06:59AM
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results Apr 24, 2023 07:33PM
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab) Mar 23, 2023 07:30AM
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer Dec 27, 2022 01:45AM


Nov 9, 2022 04:15PM NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
Nov 3, 2022 07:30AM BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Oct 11, 2022 07:30AM BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Sep 28, 2022 04:15PM Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
Sep 7, 2022 04:15PM NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
May 18, 2022 09:12PM CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
May 18, 2022 04:40PM NANOBIOTIX Provides First Quarter Operational and Financial Update
May 12, 2022 07:30AM BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
May 10, 2022 07:00AM Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 4, 2022 04:15PM NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
May 2, 2022 04:15PM New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
Apr 11, 2022 04:16PM Nanobiotix S.A. (NBTX) Reports New Preclinical Immunotherapy Data Showing Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated N
Apr 11, 2022 04:15PM NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
Apr 8, 2022 05:57PM NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
Mar 30, 2022 04:21PM  NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
Mar 16, 2022 04:15PM NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
Mar 3, 2022 07:32AM BridgeBio Pharma Inc. (BBIO) and Helsinn Group Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Mar 3, 2022 07:30AM Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Feb 24, 2022 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
Feb 9, 2022 04:15PM Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Jan 26, 2022 04:15PM NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
Jan 13, 2022 07:31AM BridgeBio (BBIO) Announces Pact with Amgen (AMGN) to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C M
Jan 13, 2022 07:30AM BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G1
Jan 10, 2022 02:00AM NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Jan 5, 2022 04:15PM NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
Nov 19, 2021 07:31AM BridgeBio Pharma Inc. (BBIO) Collaborates with Helsinn Group to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
Nov 19, 2021 07:30AM BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
Nov 15, 2021 09:00AM Citi Appointed Depositary Bank for LianBio’s Sponsored ADR Program
Nov 4, 2021 07:30AM BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update